Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINJECTIONStandard

RYBREVANT FASPRO

AMIVANTAMAB AND HYALURONIDASE-LPUJ

Standard Dose
14ML
Max Dose
Refer to approved labeling
Primary Use
Review priority: PRIORITY Marketing status: Prescription
Summary

Approval overview RYBREVANT FASPRO is listed in Drugs@FDA under application 761433 (BLA).

Review priority: PRIORITY Marketing status: Prescription Active ingredient AMIVANTAMAB AND HYALURONIDASE-LPUJ Form and strength INJECTION - 14ML Sponsor JANSSEN BIOTECH Submission history Latest submission status date: 2025-12-17 00:00:00.

Structured Monograph

Clinical summary

Approval overview RYBREVANT FASPRO is listed in Drugs@FDA under application 761433 (BLA). Review priority: PRIORITY Marketing status: Prescription Active ingredient AMIVANTAMAB AND HYALURONIDASE-LPUJ Form and strength INJECTION - 14ML Sponsor JANSSEN BIOTECH Submission history Latest submission status date: 2025-12-17 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: PRIORITY

Interaction Notes

  • No interaction notes stored yet.
RYBREVANT FASPRO (AMIVANTAMAB AND HYALURONIDASE-LPUJ) | Drug Monograph | MedicHelpline